Dexcom Reports Third Quarter 2026 Financial Results
Dexcom reported Q3 2026 revenue of $1.344 billion, up 11% year-over-year on both a reported and organic basis, with U.S. revenue up 14%. Margins improved meaningfully: GAAP operating income rose to $327.2 million (24.3% of revenue, +420 bps) and non-GAAP EPS came in at $0.73 versus $0.61 a year ago. Management again raised full-year guidance, now targeting FY26 revenue of $5.20-$5.25 billion (~12-13% growth) with non-GAAP operating margin of approximately 24%, and the board authorized a new $1.0 billion share repurchase.
Key figures
- Eps
- $0.72 GAAP diluted / $0.73 non-GAAP diluted
- Revenue
- 1344500000
- Guidance
- FY26 revenue $5.20-$5.25 billion (approximately 12-13% growth), Non-GAAP gross margin ~64%, Non-GAAP operating margin ~24%, Adjusted EBITDA margin ~32%
- Revenue Yoy
- 11%
- Adjusted ebitda
- 435200000
- Gaap gross margin
- 64.3%
- Us revenue growth
- 14%
- Buyback authorization
- 1000000000
- Gaap operating income
- 327200000
- Gaap operating margin
- 24.3%
- Non gaap gross margin
- 65.1%
- Non gaap operating income
- 339500000
- Non gaap operating margin
- 25.3%
- International revenue growth
- 5%
- Cash and marketable securities
- $1.82 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.